$CNCL
CANCER CAPITAL CORP

2024 Q2 Form 10-Q Financial Statement

#000155479524000126 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.948K $10.05K $5.699K
YoY Change 36.18% 76.35% -37.44%
Operating Profit -$3.948K -$10.05K -$5.699K
YoY Change 36.18% 76.35% -37.44%
Interest Expense $2.606K $2.606K $2.606K
YoY Change 0.0% 0.0% 19.21%
% of Operating Profit
Other Income/Expense, Net -$5.889K -$5.889K -$5.709K
YoY Change 3.15% 3.15% 12.21%
Pretax Income -$9.837K -$15.94K -$11.41K
YoY Change 14.28% 39.72% -19.65%
Income Tax
% Of Pretax Income
Net Earnings -$9.837K -$15.94K -$11.41K
YoY Change 14.28% 39.72% -19.65%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 6.150M shares 6.150M shares 6.150M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $5.157K $12.66K $17.86K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.157K $12.66K $17.86K
YoY Change -68.66% -29.12%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $5.157K $12.66K $17.86K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $5.157K $12.66K $17.86K
YoY Change -68.66% -29.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $480.3K $448.0K $440.9K
YoY Change 7.2% 1.62%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $480.3K $448.0K $440.9K
Total Long-Term Liabilities
Total Liabilities $480.3K $448.0K $440.9K
YoY Change 7.2% 1.62%
SHAREHOLDERS EQUITY
Retained Earnings -$528.4K -$518.5K -$476.2K
YoY Change 8.98% 8.89%
Common Stock $6.150K $6.150K $6.150K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$475.2K -$465.3K -$423.0K
YoY Change
Total Liabilities & Shareholders Equity $5.157K $12.66K $17.86K
YoY Change -68.66% -29.12%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$9.837K -$15.94K -$11.41K
YoY Change 14.28% 39.72% -19.65%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.500K -$4.199K
YoY Change -16.65% -44.82%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -$3.500K -$4.199K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -$3.500K -$4.199K
YoY Change -16.65%
FREE CASH FLOW
Cash From Operating Activities -$3.500K -$4.199K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001130889
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 CNCL Accounts Payable Related Parties Current2
AccountsPayableRelatedPartiesCurrent2
usd
CY2024Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2024Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
000-32363
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
CANCER CAPITAL CORP.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1803648
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
440 East 400 South
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Ste 300
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Salt Lake City
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84111
CY2024Q1 dei City Area Code
CityAreaCode
(801)
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
323-2395
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
true
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6150000 shares
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12657 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16157 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
12657 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
16157 usd
CY2024Q1 us-gaap Assets
Assets
12657 usd
CY2023Q4 us-gaap Assets
Assets
16157 usd
CY2024Q1 CNCL Accounts Payable Related Parties Current1
AccountsPayableRelatedPartiesCurrent1
7500 usd
CY2023Q4 CNCL Accounts Payable Related Parties Current1
AccountsPayableRelatedPartiesCurrent1
6000 usd
CY2024Q1 CNCL Accounts Payable Related Parties Current2
AccountsPayableRelatedPartiesCurrent2
5050 usd
CY2024Q1 CNCL Notes Payable Related Parties Classified Current1
NotesPayableRelatedPartiesClassifiedCurrent1
164125 usd
CY2023Q4 CNCL Notes Payable Related Parties Classified Current1
NotesPayableRelatedPartiesClassifiedCurrent1
164125 usd
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
130275 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
130275 usd
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
93436 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
90153 usd
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
77602 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
74996 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
447988 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
465549 usd
CY2024Q1 us-gaap Liabilities
Liabilities
447988 usd
CY2023Q4 us-gaap Liabilities
Liabilities
465549 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6150000 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6150000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6150000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6150000 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
6150 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6150 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47050 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47050 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-518531 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-502592 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-465331 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-449392 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12657 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16157 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10050 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5699 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
10050 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
5699 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10050 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5699 usd
CY2024Q1 CNCL Interest Expense Related Party1
InterestExpenseRelatedParty1
3283 usd
CY2023Q1 CNCL Interest Expense Related Party1
InterestExpenseRelatedParty1
3103 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-15939 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-11408 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-15939 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11408 usd
CY2024Q1 CNCL Cncl Earnings Per Share Basic And Diluted
CNCLEarningsPerShareBasicAndDiluted
-0.00
CY2023Q1 CNCL Cncl Earnings Per Share Basic And Diluted
CNCLEarningsPerShareBasicAndDiluted
-0.00
CY2024Q1 CNCL Cncl Weighted Average Number Of Shares Outstanding Basic
CNCLWeightedAverageNumberOfSharesOutstandingBasic
6150000 shares
CY2023Q1 CNCL Cncl Weighted Average Number Of Shares Outstanding Basic
CNCLWeightedAverageNumberOfSharesOutstandingBasic
6150000 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-411599 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11408 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-423007 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-449392 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-15939 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-465331 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-15939 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11408 usd
CY2024Q1 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
1500 usd
CY2023Q1 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
1500 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5050 usd
CY2024Q1 us-gaap Increase Decrease In Due To Other Related Parties
IncreaseDecreaseInDueToOtherRelatedParties
3283 usd
CY2023Q1 us-gaap Increase Decrease In Due To Other Related Parties
IncreaseDecreaseInDueToOtherRelatedParties
3103 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
2606 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
2606 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3500 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4199 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3500 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4199 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16157 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22055 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12657 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17856 usd
CY2024Q1 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
1500 usd
CY2024Q1 CNCL Accounts Payable Related Parties Current1
AccountsPayableRelatedPartiesCurrent1
7500 usd
CY2023Q4 CNCL Accounts Payable Related Parties Current1
AccountsPayableRelatedPartiesCurrent1
6000 usd
CY2024Q1 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.08 pure
CY2024Q1 CNCL Notes Payable Related Parties Classified Current1
NotesPayableRelatedPartiesClassifiedCurrent1
164125 usd
CY2023Q4 CNCL Notes Payable Related Parties Classified Current1
NotesPayableRelatedPartiesClassifiedCurrent1
164125 usd
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
93436 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
90153 usd
CY2024Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
CY2024Q1 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.08 pure
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
130275 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
130275 usd
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
77602 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
74996 usd

Files In Submission

Name View Source Status
0001554795-24-000126-index-headers.html Edgar Link pending
0001554795-24-000126-index.html Edgar Link pending
0001554795-24-000126.txt Edgar Link pending
0001554795-24-000126-xbrl.zip Edgar Link pending
cncl-20240331.xsd Edgar Link pending
cncl0506form10q.htm Edgar Link pending
cncl0506form10qexh31_1.htm Edgar Link pending
cncl0506form10qexh31_2.htm Edgar Link pending
cncl0506form10qexh32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cncl-20240331_cal.xml Edgar Link unprocessable
cncl-20240331_def.xml Edgar Link unprocessable
cncl-20240331_lab.xml Edgar Link unprocessable
cncl-20240331_pre.xml Edgar Link unprocessable
cncl0506form10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable